Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing TIL Harvest Site With CD8-PET Imaging in Advanced Melanoma
NCT07819474Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2027
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of crefmirlimab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Treatment Response based on RECIST 1.1 at 90 days. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
crefmirlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07819474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819474.